JW (Cayman) Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

JW (Cayman) Therapeutics heeft een totaal eigen vermogen van CN¥1.5B en een totale schuld van CN¥333.6M, wat de schuld-eigenvermogensverhouding op 22.5% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥2.0B en CN¥497.9M.

Belangrijke informatie

22.5%

Verhouding schuld/eigen vermogen

CN¥333.60m

Schuld

Rente dekkingsratio	n/a
Contant	CN¥869.03m
Aandelen	CN¥1.48b
Totaal verplichtingen	CN¥497.88m
Totaal activa	CN¥1.98b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Take Care Before Jumping Onto JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Even Though It's 26% Cheaper

Nov 12

JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Screens Well But There Might Be A Catch

Sep 25

A Piece Of The Puzzle Missing From JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) 34% Share Price Climb

May 10

Calculating The Intrinsic Value Of JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

May 03

JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?

Feb 03

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥944.4M ) 2126 } overtreffen de korte termijn passiva ( CN¥323.4M ).

Langlopende schulden: De kortetermijnactiva 2126 ( CN¥944.4M ) overtreffen de langetermijnschulden ( CN¥174.5M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 2126 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: 2126 had 5 jaar geleden een negatief eigen vermogen, maar is nu positief en is dus verbeterd.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 2126 heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of 2126 voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.

JW (Cayman) Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Take Care Before Jumping Onto JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Even Though It's 26% Cheaper

Consensus revenue estimates decrease by 32%

New minor risk - Share price stability

First half 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Screens Well But There Might Be A Catch

High number of new directors

New major risk - Revenue and earnings growth

JW (Cayman) Therapeutics Co. Ltd Announces NMPA Acceptance of Supplemental Biological License Application of Carteyva in Adult Patients with Relapsed or Refractory MCL

JW (Cayman) Therapeutics Co. Ltd to Report First Half, 2024 Results on Aug 28, 2024

JW (Cayman) Therapeutics Co. Ltd Announces CEO Changes

New minor risk - Market cap size

Now 20% overvalued after recent price rise

Now 28% overvalued after recent price rise

JW (Cayman) Therapeutics Co. Ltd Announces Research and Development Update Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China At the EURAL 2024 Congress

A Piece Of The Puzzle Missing From JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) 34% Share Price Climb

Now 52% overvalued after recent price rise

Calculating The Intrinsic Value Of JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

JW (Cayman) Therapeutics Co. Ltd, Annual General Meeting, Jun 18, 2024

Full year 2023 earnings released: CN¥1.87 loss per share (vs CN¥2.06 loss in FY 2022)

JW (Cayman) Therapeutics Co. Ltd to Report Fiscal Year 2023 Results on Mar 20, 2024

New minor risk - Market cap size

JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva in Patients with Relapsed or Refractory Mantle Cell Lymphoma

JW (Cayman) Therapeutics Co. Ltd Announces Resignation of Xin Fu as Chief Financial Officer

New minor risk - Share price stability

Consensus revenue estimates decrease by 26%, EPS upgraded

First half 2023 earnings released: CN¥0.93 loss per share (vs CN¥1.05 loss in 1H 2022)

JW (Cayman) Therapeutics Co. Ltd Announces Board Changes

JW (Cayman) Therapeutics Co. Ltd to Report First Half, 2023 Results on Aug 29, 2023

Consensus revenue estimates decrease by 20%, EPS upgraded

Non-Executive Director recently sold HK$2.3m worth of stock

Non-Executive Director recently sold HK$2.0m worth of stock

JW (Cayman) Therapeutics Co. Ltd Announces Resignation of Chi Shing Li as Independent Non-Executive Director and the Chairman of the Remuneration Committee of the Board and Nomination Committee of the Board, Effective January 1, 2023

JW (Cayman) Therapeutics Co. Ltd Provides Update on Latest Clinical Data on Carteyva® in Follicular Lymphoma

Less than half of directors are independent

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma

First half 2022 earnings released: CN¥1.05 loss per share (vs CN¥0.71 loss in 1H 2021)

JW (Cayman) Therapeutics Co. Ltd to Report First Half, 2022 Results on Aug 30, 2022

JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma

JW Therapeutics Presents Latest Data of Three Clinical Studies on Carteyva at 2022 American Society of Clinical Oncology Annual Meeting

JW (Cayman) Therapeutics Co. Ltd, Annual General Meeting, Jun 29, 2022

Less than half of directors are independent

JW Therapeutics Announces Its Cell Immunotherapy Drugs Have Successfully Benefited 200 Chinese Patients

JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva® in Pediatric and Young Adult Patients

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China

JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma

Consensus revenue estimates fall by 33%

Consensus revenue estimates increase by 23%

JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma

Consensus forecasts updated

Independent Non-Executive Director Yanling Cao has left the company

Non-Executive Director Hans Edgar Bishop has left the company

Consensus forecasts updated

Non-Executive Director recently sold HK$13m worth of stock

JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129

JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)

JW (Cayman) Therapeutics Co. Ltd Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China

Company Secretary Suet Wing Leung has left the company

JW (Cayman) Therapeutics Co. Ltd to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$49.80

JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?

JW (Cayman) Therapeutics Co. Ltd has completed an IPO in the amount of HKD 2.32507 billion.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven